SABS
SAB Biotherapeutics·NASDAQ
--
--(--)
--
--(--)
2.69 / 10
Underperform
SAB Biotherapeutics' fundamental assessment is subpar (2.7/10). Key drawbacks include weak revenue-to-market-value and gross-profit-margin metrics, although PB-ROE and profit-to-market-value show some promise. This combination points to constrained growth prospects and elevated risk.
Analysis Checks(7/10)
Revenue-MV
Value-0.26
Score1/3
Weight9.42%
1M Return5.63%
Value-0.26
Score1/3
Weight9.42%
1M Return5.63%
Gross profit margin (%)
Value36.70
Score1/3
Weight0.27%
1M Return0.22%
Value36.70
Score1/3
Weight0.27%
1M Return0.22%
Net income-Revenue
Value-0.15
Score2/3
Weight13.37%
1M Return8.04%
Value-0.15
Score2/3
Weight13.37%
1M Return8.04%
Current assets turnover ratio
Value0.00
Score2/3
Weight2.34%
1M Return1.75%
Value0.00
Score2/3
Weight2.34%
1M Return1.75%
Asset-MV
Value-0.51
Score1/3
Weight18.47%
1M Return9.84%
Value-0.51
Score1/3
Weight18.47%
1M Return9.84%
Inventory turnover ratio
Value47.88
Score3/3
Weight8.63%
1M Return5.89%
Value47.88
Score3/3
Weight8.63%
1M Return5.89%
Profit-MV
Value3.94
Score2/3
Weight13.19%
1M Return7.95%
Value3.94
Score2/3
Weight13.19%
1M Return7.95%
PB-ROE
Value-0.94
Score2/3
Weight19.27%
1M Return11.23%
Value-0.94
Score2/3
Weight19.27%
1M Return11.23%
Fixed assets turnover ratio
Value0.00
Score3/3
Weight1.99%
1M Return1.53%
Value0.00
Score3/3
Weight1.99%
1M Return1.53%
Cash-MV
Value-0.07
Score2/3
Weight13.07%
1M Return7.78%
Value-0.07
Score2/3
Weight13.07%
1M Return7.78%
Revenue-MV
Value-0.26
Score1/3
Weight9.42%
1M Return5.63%
Value-0.26
Score1/3
Weight9.42%
1M Return5.63%
Inventory turnover ratio
Value47.88
Score3/3
Weight8.63%
1M Return5.89%
Value47.88
Score3/3
Weight8.63%
1M Return5.89%
Gross profit margin (%)
Value36.70
Score1/3
Weight0.27%
1M Return0.22%
Value36.70
Score1/3
Weight0.27%
1M Return0.22%
Profit-MV
Value3.94
Score2/3
Weight13.19%
1M Return7.95%
Value3.94
Score2/3
Weight13.19%
1M Return7.95%
Net income-Revenue
Value-0.15
Score2/3
Weight13.37%
1M Return8.04%
Value-0.15
Score2/3
Weight13.37%
1M Return8.04%
PB-ROE
Value-0.94
Score2/3
Weight19.27%
1M Return11.23%
Value-0.94
Score2/3
Weight19.27%
1M Return11.23%
Current assets turnover ratio
Value0.00
Score2/3
Weight2.34%
1M Return1.75%
Value0.00
Score2/3
Weight2.34%
1M Return1.75%
Fixed assets turnover ratio
Value0.00
Score3/3
Weight1.99%
1M Return1.53%
Value0.00
Score3/3
Weight1.99%
1M Return1.53%
Asset-MV
Value-0.51
Score1/3
Weight18.47%
1M Return9.84%
Value-0.51
Score1/3
Weight18.47%
1M Return9.84%
Cash-MV
Value-0.07
Score2/3
Weight13.07%
1M Return7.78%
Value-0.07
Score2/3
Weight13.07%
1M Return7.78%
Is SABS undervalued or overvalued?
- SABS scores 2.69/10 on fundamentals and holds a Premium valuation at present. Backed by its 31.55% ROE, 16338.32% net margin, -5.36 P/E ratio, 1.20 P/B ratio, and 92.06% earnings growth, these metrics solidify its Underperform investment rating.
